Selective GABA Transporter Inhibitors Tiagabine and EF1502 Exhibit Mechanistic Differences in Their Ability to Modulate the Ataxia and Anticonvulsant Action of the Extrasynaptic GABAA Receptor Agonist Gaboxadol
Authors:
- Bjarke EbertBEBjarke Ebert
- Rasmus P. ClausenRCRasmus P. Clausen
- Povl Krogsgaard-LarsenPKPovl Krogsgaard-Larsen
- Arne SchousboeASArne Schousboe
- H. Steve WhiteHWH. Steve White
- 1 July 2011
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 338 (1) , 214-219
Abstract
Modulation of the extracellular levels of GABA via inhibition of the synaptic GABA transporter GAT1 by the clinically effective and selective GAT1 inhibitor tiagabine [(R)-N-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid; Gabitril] has proven to be an effective treatment strategy for focal seizures. Even though less is known about the therapeutic potential of other GABA transport inhibitors, previous investigations have demonstrated that N-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-hydroxy-4-(methylamino)-4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol (EF1502), which, like tiagabine, is inactive on GABAA receptors, inhibits both GAT1 and the extrasynaptic GABA and betaine transporter BGT1, and exerts a synergistic anticonvulsant effect when tested in combination with tiagabine. In the present study, the anticonvulsant activity and motor impairment associated with systemic administration of gaboxadol (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol), which, at the doses used in this study (i.e., 1–5 mg/kg) selectively activates extrasynaptic α4-containing GABAA receptors, was determined alone and in combination with either tiagabine or EF1502 using Frings audiogenic seizure-susceptible and CF1 mice. EF1502, when administered in combination with gaboxadol, resulted in reduced anticonvulsant efficacy and Rotarod impairment associated with gaboxadol. In contrast, tiagabine, when administered in combination with gaboxadol, did not modify the anticonvulsant action of gaboxadol or reverse its Rotarod impairment. Taken together, these results highlight the mechanistic differences between tiagabine and EF1502 and support a functional role for BGT1 and extrasynaptic GABAA receptors.Keywords
This publication has 32 references indexed in Scilit:
- GABAAreceptor α4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadolProceedings of the National Academy of Sciences, 2006
- Pharmacological Characterization of Agonists at δ-Containing GABAA Receptors: Functional Selectivity for Extrasynaptic Receptors Is Dependent on the Absence of γ2The Journal of Pharmacology and Experimental Therapeutics, 2006
- Gaboxadol — a new awakening in sleepCurrent Opinion in Pharmacology, 2006
- First Demonstration of a Functional Role for Central Nervous System Betaine/γ-Aminobutyric Acid Transporter (mGAT2) Based on Synergistic Anticonvulsant Action among Inhibitors of mGAT1 and mGAT2The Journal of Pharmacology and Experimental Therapeutics, 2005
- Correlation between Anticonvulsant Activity and Inhibitory Action on Glial γ-Aminobutyric Acid Uptake of the Highly Selective Mouse γ-Aminobutyric Acid Transporter 1 Inhibitor 3-Hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and Its N-Alkylated AnalogsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Neuronal and glial localization of GAT-1, a high-affinity ?-aminobutyric acid plasma membrane transporter, in human cerebral cortex: With a note on its distribution in monkey cortexJournal of Comparative Neurology, 1998
- EFFICIENT DESIGNS FOR STUDYING SYNERGISTIC DRUG COMBINATIONSLife Sciences, 1997
- Cloning and Expression of a Betaine/GABA Transporter from Human BrainJournal of Neurochemistry, 1995
- Statistical analysis of drug combinations for synergismPain, 1992
- Probit AnalysisTechnometrics, 1973